Three phase 1 candidates

Based on the PhRMA report, “Medicines in Development for Women“, I added three candidates to the phase 1 list:

1. PDA-001 (cenplacel-L) Celgene Cellular Therapeutics
2. GSK1223249 (NOGO-A mAb) (GlaxoSmithKline)
3. GSK2018682 (sphingosine-1 phosphate receptor-1) (GlaxoSmithKline)

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: